Recurrent Melanoma Completed Phase 2 Trials for Cediranib (DB04849)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00243061AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaTreatment